Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» GSK Receives Positive Opinions In Europe For Tyverb® (lapatinib) And Votrient™ (pazopanib)
GSK Receives Positive Opinions In Europe For Tyverb® (lapatinib) And Votrient™ (pazopanib)
GSK Receives Positive Opinions In Europe For Tyverb® (lapatinib) And Votrient™ (pazopanib)
Submitted by
admin
on February 20, 2010 - 11:50am
Source:
Medical News Today
News Tags:
GSK
Tyverb
Votrient
breast cancer
Headline:
GSK Receives Positive Opinions In Europe For Tyverb® (lapatinib) And Votrient™ (pazopanib)
Do Not Allow Advertisers to Use My Personal information
